|

Is Ibogaine FDA-Approved for OUD or PTSD? What the October 2026 RFI Means

ByLife Choice Note

Short answer: No. The FDA’s October 2026 action did not approve ibogaine for opioid use disorder (OUD), post-traumatic stress disorder (PTSD), or any other condition. It opened a request for information (RFI) about how tightly controlled, early-phase ibogaine trials might be designed. An RFI is a call for evidence and comments—not a marketing authorization, treatment recommendation, or finding that benefits outweigh risks.

What did the FDA announce in October 2026?

The FDA announced the RFI on October 5, 2026. The formal Federal Register notice was published October 6.

  • Jurisdiction: United States, under the FDA drug-development framework
  • Who it concerns: trial sponsors, researchers, clinicians, patients and members of the public who can provide relevant data or experience
  • Initial federally supported populations: adults with OUD and adults with PTSD
  • Docket: FDA-2026-N-10429
  • Comment deadline: November 20, 2026, at 11:59 p.m. Eastern Time

Why is the FDA asking about trial design before efficacy?

Ibogaine has unresolved, potentially life-threatening risks. The notice highlights marked QTc prolongation, which can trigger a dangerous ventricular rhythm called torsades de pointes, as well as nonclinical neurotoxicity and uncertainty about a safe human starting dose. Acute effects can also include severe ataxia, seizures, impaired cognition or balance, psychosis and other psychiatric symptoms.

That risk profile explains why the agency is not describing routine outpatient treatment. Its preliminary model is a small, open-label, single-dose, sequential dose-escalation study. A starting dose would need scientific justification and would not exceed 10 mg/kg. Each participant could be dosed one at a time, with review before escalation.

What safeguards is the FDA considering?

The RFI sketches an inpatient setting able to manage a life-threatening arrhythmia: continuous cardiac monitoring, an advanced-cardiac-life-support team, bedside defibrillation, emergency pacing and ventilatory support. Monitoring might continue until rhythm abnormalities resolve and QTc returns near baseline, potentially for 36 hours or longer.

The FDA also asks about medication interactions, CYP2D6 metabolism, neurologic and cognitive follow-up, stopping rules, independent data monitoring and strict eligibility criteria. These are questions for controlled research. They are not a checklist that makes ibogaine self-administration or commercial treatment travel safe.

What does the existing human evidence show?

A 2022 open-label observational study evaluated 10 mg/kg ibogaine hydrochloride in people with OUD undergoing opioid withdrawal. The investigators reported clinically relevant, reversible QTc prolongation and severe transient ataxia. The design was small, uncontrolled and focused on safety; it cannot establish that ibogaine is an effective OUD treatment.

A separate 2024 Nature Medicine study followed 30 Special Operations Forces veterans with traumatic brain injury who had independently arranged magnesium–ibogaine treatment at a Mexican clinic. Disability and psychiatric scores improved through one month, but there was no randomized control group. The highly selected population, self-selection, short follow-up and combined magnesium–ibogaine intervention limit generalization to ordinary PTSD care or OUD.

Does an IND study mean the drug is approved?

No. The FDA says it has allowed an early-phase study of noribogaine hydrochloride—an ibogaine metabolite—to proceed under an Investigational New Drug application for possible alcohol use disorder treatment. An IND allows a study to proceed under regulatory oversight; it is not approval to market the product.

For marketing approval, a sponsor would still need substantial evidence of effectiveness for a defined use, adequate evidence that benefits outweigh risks, and reliable manufacturing and quality information. The RFI expressly says it does not establish enforceable requirements, represent final FDA views, or predetermine action on any future IND.

What the 10 mg/kg figure does—and does not—mean

The figure is not a recommended dose for patients. It is the upper bound of a proposed starting-dose concept for discussion in an initial, closely monitored trial. The FDA notes that published reports often lack reliable product characterization, participant-level data and complete safety, efficacy and pharmacokinetic information. Product purity and potency can also vary, making dose comparisons misleading.

Scope and evidence limits

  • The action applies to U.S. drug-development oversight; it does not determine legality or clinical practice in other countries.
  • FDA is seeking information, not approving ibogaine or predicting an approval date.
  • Adults with OUD and adults with PTSD are research priorities, not populations for whom benefit has been established.
  • Proposed monitoring, eligibility and stopping rules remain preliminary and may change after review of comments.
  • Available human studies are generally small and often open-label or observational, limiting causal conclusions and detection of uncommon harms.
  • This article explains regulatory and research sources. It does not diagnose a condition, recommend treatment or advise participation in a particular trial.

Primary sources checked

Prepared by: Life Choice Note, an independent personal health-information explainer
Reviewed: October 7, 2026
Purpose: General explanation of official regulatory material and original research. This article does not provide individual diagnosis, treatment instructions, or guarantees of safety or benefit.

Related guides